• Aurinia reports favourable assessment of LUPKYNIS in ICER pharmaceutical-technology
    March 18, 2021
    Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis.
PharmaSources Customer Service